Biopeople

Founder on board

Norway

Founder on board

25.05.2016 - Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.

Bohan founded NattoPharma in 2004. He later founded NoLabel and NutriCon, a nutraceutical and pharmaceutical communications companyl, respectively. Bohan is also a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.

Simultaneously with Bohan’s reelection as chair, the Board of Directors has been extended by two members: Stefan Halldén and Annette Elmqvist.

http://www.european-biotechnology-news.com/people/bio-people/2016/frode-bohan.html

UK

14.01.2016 James Sandy is taking over the clinical development of Immunocore’s immuno-oncology product pipeline as the company’s new Chief Development Officer. Sandy has 25 years of experience in the biotech and pharma sector.

© Immunocore

Most recently, he was Chief Development Officer at UK-based specialty pharmaceutical company Creabilis. Previously, Sandy held senior positions at Pfizer, among them Head of European and Asian Development Operations, Development Team Leader within the Gastrointestinal Therapeutic Area and Oncology Therapeutic Area Head, Europe. 

At the same time, Immunocore, a developer of T cell receptor-based biologicals for the treatment of cancer and other diseases, also appointed Julian Hirst as Director of Corporate Finance. 

Netherlands

11.01.2016 In December, Koos van Haasteren was appointed CEO of the Dutch sister companies Alloksys Life Sciences and Amrif. The new lead will be responsible for driving the development of the biopharma’s human recombinant RESCAP platform for both acute clinical settings and chronic diseases.

© Alloksys

Van Haasteren has previously worked at Saudi Arabian chemicals company SABIC, as well as at DSM and KPMG.

UKDenmark

07.01.2016 London-based biotech Tiziana Life Sciences has hired James Tripp as its new Chief Operating Officer and Head of Global Clinical Operations. In his new role, Tripp will be responsible for all operations, including global clinical development for Tiziana.

© Tiziana

Tripp has over twenty years' experience in biopharmaceutical operations. Before joining Tiziana, he was Director, Clinical Management at Danish Novo Nordisk, A/S. Previously, he had worked at Regeneron Pharmaceuticals, Schering-Plough, Bayer and Roche.

GermanyEU

04.01.2016 Martinsried-based Medigene AG has appointed current CSO Doloris Schendes to take over as new CEO of the Frankfurt-listed company. Medigene’s erstwhile CEO Frank Mathias is to be nominated for the Supervisory Board. The changes are taking effect 1 February, 2016.

© Medigene

Schendel holds a PhD in Genetics from the University of Wisconsin and is the author of more than 200 scientific publications. She has been a member of the scientific review board in several research organisations, among them the German Research Foundation, German Cancer Aid and the European Research Council.

Schendel joined Medigene in 2014 when the company acquired Trianta Immunotherapy. At Trianta, Schendel held the position of Managing Director. Prior to this, she was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich, and before that, she served as a University Professor for Immunology at Ludwig Maximilian University.

Belgium

28.12.2015 Since December, clinical immunologist Robert K. Zeldin is leading the global clinical development, regulatory and medical affairs activities of Belgian biopharma company Ablynx.

© Ablynx

The newly appointed Chief Medical Officer earned his M.D. from the Tufts University School of Medicine in Boston and has held senior level clinical development positions at pharmaceutical companies, among them Merck and Novartis.

In his previous roles, Zeldin headed teams in immunology, respiratory, dermatology and cardiovascular disease where he was responsible for clinical development through to commercialisation and life cycle management. 

Zeldin replaces Dominique Tersago as CMO.

PolandGermany

23.12.2015 There are a number of new faces at Polish pharma company Polpharma. Newest addition is Federico Pollano, who took over as Director Contract Manufacturing and Business Development in October.

© F. Pollano

Before switching to Polpharma, Pollano spent eight years as CEO and Managing Director of German company Richter-Helm BioLogics GmbH & Co. KG. He started out at the company as Executive Manager of the pharmaceutical division. Previously, he headed the Business Development unit of BioGeneriX AG.

Switzerland

21.12.2015 James Bradner is set to take over the lead of the Novartis Institutes for Bio­medical Research (NIBR) in March. He has also been appointed a member of the Executive Committee of Novartis and will be based at the NIBR headquarters in Cambridge, US.

© Novartis

Bradner, a graduate of Harvard College and the University of Chicago Medical School, leads a discovery chemistry lab at the Dana-Farber Cancer Institute, and is an investigator in Dana-Farber’s Department of Medical Oncology as well as a a member of the affiliated faculty at Harvard Stem Cell Institute of Harvard University. As an avid proponent of open-source drug discovery, Bradner has innovated a drug discovery model, which gives researchers unrestricted access to first-in-class drugs.

UKGermany

17.12.2015 Silence Therapeutics plc, developer of novel RNAi therapeutics, has appointed Alistair Gray as Non-Executive Director. He will also chair the Audit Committee.

© Silence

Having trained as an accountant, Gray’s early career was in senior management positions with Unilever and John Wood Group PLC. He was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group.

Later, Gray founded Genesis Consulting and, most recently, Renaissance & Company. He is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. He chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Gray also served as a Fellow of the Institute of Directors and Institute of Consultants.

EUIreland

14.12.2015 In mid-September, Pierre Meulien took up his duties as Executive Director of the Innovative Medicines Initiative (IMI). He previously served as President and Chief Executive Officer of a not-for-profit organisation Genome Canada.

© IMI

Meulien, who holds a PhD in molecular biology from the University of Edinburgh, came to Genome Canada in 2010 from Genome British Columbia, where he held the position of Chief Scientific Officer. Before that, he was founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland).

Germany

10.12.2015 Together with its radically new brand, Merck KGaA is also bringing in a new Chair. After nine years at the helm of Merck, Karl-Ludwig Kley is retiring and making way for his successor Stefan Oschmann.

© Merck

Oschmann, currently Deputy Chairman of the Executive Board and Deputy CEO of Merck, has been a member of the Board since 2011. He switched to the German company from US competitor MSD Merck Sharp & Dohme, where he held the position of President of Emerging Markets. He is president of the International Federation of Pharmaceutical Manufacturers & Associations and Vice President of European Federation of Pharmaceutical Industries and Associations.

Vorherige Seite4/35Nächste Seite

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • NORDIC NANOVECTOR (N)27.10 NOK10.61%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • 4SC (D)2.38 EUR-8.11%
  • RENEURON (UK)3.38 GBP-3.43%

TOP

  • GALAPAGOS (B)51.60 EUR30.0%
  • NICOX (F)10.95 EUR28.1%
  • GENMAB (DK)1194.00 DKK24.0%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.3%
  • 4SC (D)2.38 EUR-27.9%
  • MOBERG PHARMA (S)38.70 SEK-20.4%

TOP

  • KARO BIO (S)30.30 SEK1961.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.95 EUR488.7%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.0%
  • BB BIOTECH (D)44.70 EUR-84.3%
  • BIOTEST (D)17.05 EUR-78.3%

No liability assumed, Date: 30.05.2016

Events

All Events

Partner-Events

Basel (CH)

Chemspec Europe 2016